Company news
Renovorx, Inc. (NASDAQ:RNXT) news
Every Renovorx, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Dr...
August 25, 2026
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
August 21, 2026
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therape...
August 20, 2026
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
August 11, 2026
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, Augu...
August 4, 2026
RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET
July 29, 2026
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
June 11, 2026
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
June 4, 2026
RenovoRx Announces FDA Orphan Drug Designation Granted, Oxaliplatin for the Treatment of Pancreatic Cancer
May 29, 2026
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
May 28, 2026
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
May 26, 2026
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
May 14, 2026
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
April 29, 2026
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at t...
April 23, 2026
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific...
April 14, 2026
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the ...
April 8, 2026
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
April 1, 2026
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
March 30, 2026
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
March 26, 2026
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
March 23, 2026
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
March 20, 2026
RenovoRx Announces $10 Million at Market Private Placement
March 18, 2026
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
February 27, 2026
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
February 26, 2026
RenovoRx Establishes RenovoCath® Medical Advisory Board
February 10, 2026
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
February 5, 2026
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
February 4, 2026
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
January 28, 2026
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Ce...
January 20, 2026
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026
January 14, 2026
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026
January 8, 2026
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
December 11, 2025
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th
December 1, 2025
RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th
November 19, 2025
RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Up...
November 13, 2025
RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD
November 6, 2025
RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th
November 4, 2025
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET
October 27, 2025
RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD
October 9, 2025
RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites
September 25, 2025
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th
September 11, 2025
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 27th Annual Global Investment Conference in New York City, September 8-10, 2025
August 20, 2025
RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recomm...
August 14, 2025
RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire
August 6, 2025
RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors
July 28, 2025
RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET
July 14, 2025
RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights
May 15, 2025
RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st
May 14, 2025
U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform
May 6, 2025
RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
May 1, 2025